StockWatch
·

XPRO INDIA LTD. Q2 FY27 Results

XPROINDIAQ2 FY27 Results
Filing
Result:Good· Market: Surged#Broad based#Margin expansion

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue176.691.3%47.4%
Total Income180.661.3%45.7%
Expenditure170.212.0%45.1%
PBT10.469.5%56.0%
Net Profit7.195.7%44.7%
OPM—
NPM3.98%0.30pp0.03pp
EPS3.224.7%50.5%
View full financials

Industrials core metric (revenue growth) accelerated 47% YoY with operating margin expansion to 8.41% from 6.11%, though flat NPM YoY on higher depreciation and a forex swing caps it just below a standout.

XPRO INDIA · Q2 FY27 · THE VERDICT

New Capacity, Compressed Margins — The Long Ramp Ahead

Revenue surged 47% year-over-year, but profit fell quarter-over-quarter as the Barjora dielectric film line ramps up. Management has extended the margin recovery timeline to 1–2 years, signaling near-term pressure ahead.

09 Nov 2026 · 6 min read
Q2 Revenue

₹176.7 Cr

+47.4% YoY, +1.3% QoQ

Q2 Net profit

₹7.2 Cr

+44.7% YoY, –5.7% QoQ

Net margin

4.0%

down from ~5–6% prior

The headline looks strong — ₹176.7 crore in quarterly revenue, up 47% year-over-year. But flip to the bottom line and the real story emerges. Net profit fell 5.7% quarter-over-quarter to ₹7.2 crore, even as the top line grew 1.3% sequentially. That inversion — growth at the top, contraction at the bottom — is the defining signal of Q2: new capacity is being built, not yet generating returns.

Why the margin compressed

The Barjora dielectric film line, commissioned in March 2026, is in early ramp. Management reported 35% quarter-over-quarter production growth on the new line — solid progress, but still only ramping. The costs of bringing this capacity online — depreciation (heavy capex of ₹64.3 crore in H1 alone), operating costs at partial utilization, freight and shipping volatility, and most critically, competitive pricing pressure — are hitting margins in real time. Management acknowledged it: 'Operating costs, depreciation, and finance costs of the new capacity continue to weigh on profitability.' The segment that should drive premium returns, dielectric films, grew 64% year-over-year, but pricing power eroded as new competitors entered the space. Exports nearly doubled (₹17.1 crore H1, +82% year-over-year), a win, but at lower margins. The result: net margin compressed to 4.0% in Q2 from the prior run-rate of 5–6%.

Q2 profitability signals
-12.079.8831.8253.7747.4Revenue growth44.7PAT growth YoY-5.7PAT change QoQ
Top-line momentum masks margin pressure. Revenue +47% YoY masks the -5.7% QoQ PAT decline.
Management's claims vs. what holds up
Management claimWhat the data showsVerdict
Dielectric film exports nearly doubled YoYH1 exports ₹17.1 Cr vs ₹9.39 Cr prior, +82% YoYSupported
Barjora new line production grew 35% Q-o-QConfirmed in Q&A; Q1 → Q2 production +35%Supported
Expected to exceed ₹700 Cr revenue if market sustainsH1 ₹351.1 Cr annualizes to ~₹700 Cr; contingent forecastSupported
80% utilization in Q4 = ~900 MT from new lineAnalyst confirmed 80% of 4 MT nameplate = 900 MTSupported
Margin recovery to 25% consolidated in 1–2 yearsStated as directional target, not year-specificSupported (vague on timing)

What changed on this call

Three key timeline revisions signal management is taking a longer view on execution. First, Barjora utilization: In prior guidance (FY26 call), the company guided for 50% utilization in FY26. Current guidance is 70–80% utilization by Q4 FY27 — a three-quarter extension. Second, UAE timeline: The third dielectric line in the UAE was supposed to reach commercial production by Q3 FY27 (Oct–Dec 2026). Management now expects dry runs in late December 2026 or January 2027, with commercial production likely in Q1 FY28 — a 3–6 month slip. Third, margin recovery: Rather than near-term accretion, the company repositioned the 25% consolidated margin target as a 1–2 year multi-year journey (FY28–29). In each case, the message is the same: this is a multi-year ramp, not a near-term accretion story.

Bull-bear ledger
  • Revenue growth (47% YoY) materially ahead of market

  • Dielectric film exports doubled H1 (+82% YoY); customer momentum strong

  • New Barjora line commissioned on time (March 2026); producing

  • Long-term margin recovery path (25% target) credible via capacity + mix

  • Market tailwind (EV, renewable energy) durable

  • Margin compression (-5.7% QoQ PAT) despite revenue beat signals near-term pain

  • Pricing power weak; new competitors entering; management evasive on Q4 guidance

  • Barjora ramp at only 35% Q-o-Q; needs 2–3x to hit Q4 target

  • UAE timeline slipped 3–6 months (Q3 → Q1 FY28); capex risk

  • Capex intensity (18% of revenue) will pressure returns for 2–3 years

Risks, ranked by how much they should concern a holder

Margin compression near-term (PAT -5.7% QoQ despite revenue growth)

High

New line operating costs + pricing pressure are eroding returns. If compression extends into Q4 FY27, margin recovery timeline shifts further out.

Capacity utilization miss (target 70–80% Q4, currently 35% Q-o-Q ramp)

High

Requires 2–3x monthly growth in 2 quarters. Miss would signal demand or pricing headwinds, delaying recovery path by 1–2 quarters or more.

Pricing power erosion (new competitors, management evasion on Q4 guidance)

Medium

Dielectric films are high-margin (35–55% EBITDA), but competitive entry is real. If pricing falls below modal ₹470–480/kg, margin recovery timeline extends.

UAE timeline slip (Q3 FY27 → Q1 FY28, 3–6 months)

Medium

Delays capex payoff and FY28 earnings accretion. Each quarter of slip costs material potential revenue and extends cash flow strain.

Raw material volatility (PP prices ±20–30% per quarter; pass-through lagged)

Medium

If polymer prices rebound and pass-through lags further, margin mix will deteriorate. Management has no hedging program disclosed.

How the street is positioned

Price, flows, and insider activity

Stock price

Status

₹1101.7 (Nov 9, 2026)

What it signals

Neutral trend. Down 34.3% from all-time high ₹1677, up 39.8% from 52-week low ₹788. Trading below SMA200 (₹1121) and SMA50 (₹1135). RSI 53.4 (neutral). In drawdown, not making new highs.

FII/DII flows

Status

FII 13.81% (−0.08pp QoQ), DII 2.94% (+0.06pp QoQ)

What it signals

Flat. No major institutional repricing post-result. FII trimmed slightly; DII flat. Suggests market waiting for Q4 utilization + margin recovery proof.

Insider activity

Status

Ashish Kacholia sold ₹2.22 Cr @ ₹970.11 (Oct 19, 2026)

What it signals

Insider sold near 52-week lows, NOT near highs. This was before the Q2 result, suggesting either accumulation opportunity at lower levels or transaction unrelated to quarter outlook. Contrarian signal for patient investors.

What to watch next (next 1–2 quarters)
  • 1 · Q4 FY27 capacity utilization ramp

    Management targets 70–80% utilization (900 MT) on Barjora by Q4. If achieved, sets up FY28 earnings recovery and validates multi-year thesis. If stuck at 35–50%, margin recovery timeline extends by 1–2 quarters and demand/pricing headwinds are real.

  • 2 · UAE dry-run success (Dec 2026–Jan 2027)

    Current guidance: dry runs Dec–Jan, commercial production Q1 FY28. Any further delays extend capex payoff. Any acceleration would re-rate upside. Timeline visibility is critical for investor confidence.

  • 3 · Pricing hold on dielectric films (Q4 FY27)

    Management dodged Q4 price guidance, saying 'the world is volatile.' Modal price ₹470–480/kg for standard 3.5-micron dielectric is the level to watch. If pricing compresses further (new entrants, demand slack), margin recovery timeline extends significantly.

This is a steady execution story, not a step-change. XPRO is building the right capacity (high-margin dielectric films) in the right markets (exports +82% H1). But the timeline is now clearly multi-year, not quarters. Management extended the Barjora ramp (from FY26 to Q4 FY27), delayed UAE (Q3 to Q1 FY28), and repositioned margin recovery to 1–2 years out. Near-term (Q4 FY27–Q1 FY28) will be noisy: utilization ramps, pricing holds or softens, capex continues. Long-term (FY28–29) is more credible: if the new capacity absorbs and product mix shifts to premium dielectric films, the 25% consolidated margin target is plausible.

The number to track: Barjora line utilization as a % of nameplate 4,000 MT. If tracking toward 70–80% by Q4, the multi-year thesis holds and a FY28 rerating is possible. If stuck at 35–50%, demand or pricing headwinds are real and recovery timeline extends.

Rating: Hold. Conviction on long-term execution (capacity, product mix, market tailwind) is credible. But near-term (next 2–3 quarters) will require proof — utilization ramp and pricing stability. Insider selling at lows (₹970) is a contrarian signal for patient investors, but the stock needs Q4 results and Q1 FY28 updates before a rerate higher. For now, steady execution on a multi-year timeline: hold, don't chase.

Informational and educational content only. Not investment advice.